Jennifer Taubert

The ongoing tumult at J&J now involves a pending corporate breakup—but Taubert seems poised to come out on top. She runs the blockbuster pharma business that J&J wants to keep as it tries to shed its consumer products operation. Taubert’s unit grew revenue 14.3% in 2021 to $52.1 billion. However, the struggling COVID vaccine she oversaw slipped further in the U.S. this year; the FDA limited it to use as a last resort, citing higher risk of blood clots.